FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer
64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.